引人关注的是，东方雨虹在2023年和2024年这两年的第四季度净利润表现出大幅变脸。如2023年第一季 度至第三季度，公司分别实现净利润3.86亿元、9.49亿元、10.19亿元，分别同比增长21.53%、46.15%、 48.05%。但2023年第四季度公司净利润为亏损8016.82万元，同比下降117.18%。2024年第一季度至第三 季度，公司分别实现净利润3.48亿元、5.96亿元、3.34亿元，分别同比下降9.81%、37.23%、67.23%。而 2024年第四季度，公司净利润突然变脸为亏损11.69亿元，同比下降1358.30%。 虽然业绩承压，但东方雨虹（002271）股价近半年表现相对强势，而近期更是出现加速上涨态势。不 过，东方雨虹实控人却抛出减持计划。1月27日晚，东方雨虹发布控股股东减持计划公告。公司控股股 东、实际控制人李卫国先生计划在公告披露之日起15个交易日后的3个月内(自2026年2月26日至2026年5 月25日)，以大宗交易或集中竞价交易方式减持公司股份不超过7166.08万股(占本公司总股本比例不超过 3%)。 公司2025年第四季度的净利润有没有可能出现类似变脸的情况呢 ...

1月23日，长盈精密（300115）公布了2025年股票期权激励计划授予激励对象名单，拟以当日为授予日，向符合条件的870名激励对象授予1426.20万份股 票期权。 在此之前，长盈精密一份范围相对较小的员工持股计划已引发市场侧目。多位高管出现"前脚预披露减持计划、后脚低价参与员工持股"的紧密安排，引发 外界对其是否存在"高抛低吸"套利的质疑。 接受上证报采访的律师分析称，从现有规则看，减持与员工持股计划适用两套独立规则，类似操作在形式上合规。但高管在短期内先披露减持计划，后以 显著低于市价及减持价格的价格参与员工持股计划，客观上形成了价差与套利空间。基于此，监管考虑可补充二者衔接的限制性条款，防范规则层面的灰 色地带。 减持、员工持股计划"前后脚"披露 作为市场热捧的人形机器人概念股，长盈精密当前股价较2025年初已经翻倍。该公司主要从事电磁屏蔽件、精密连接器、LED精密支架等电子零组件的研 发、生产和销售，亦为人形机器人的传动件、结构件、执行器、传感器、变速齿轮、线束、电机等提供核心零部件。 回溯公告来看，长盈精密五名董事、高管此前于2025年12月17日预披露了减持计划。 | | 減持原 | 股份来 | ...

Group 1 - The company's stock price has increased significantly, with a cumulative rise of 80.52% since December 1, 2025, outperforming the Shanghai Composite Index, while the company's fundamentals have not changed significantly [2][3] - The company's static price-to-earnings (P/E) ratio was reported as negative on January 9, 2026, deviating from the industry average P/E ratio of 42.47 for specialized equipment manufacturing and 89.56 for the aerospace industry [4] - The stock turnover rate has increased significantly since December 30, 2025, with a cumulative turnover rate of 169.27% and an average daily turnover rate of 21.16%, indicating heightened trading activity [5] Group 2 - The company anticipates a net loss of approximately 220 million yuan for the fiscal year 2025, with a net profit of approximately -210 million yuan after excluding non-recurring gains and losses [6] - The company's main business involves specialized equipment, modified vehicles, flexible pipes, pressure vessels, and artistic engineering, with applications in various sectors such as petrochemicals, hydropower, nuclear power, and energy equipment, and no significant changes in revenue structure are expected in the short term [7]

Group 1 - On the first trading day of 2026, several companies with market capitalizations below 10 billion announced the early termination of their share reduction plans [1][2] - Hezhong China disclosed that its controlling shareholder planned to reduce its stake by up to 796.1 million shares, representing 2% of the total share capital, but decided to terminate the plan early due to meeting funding needs and expressing confidence in the company's future [1] - Hezhong China's stock price has been rising since late October, despite warnings of performance decline and losses due to macroeconomic changes and policy adjustments in the medical industry [1] Group 2 - As of January 5, Hezhong China's total market value is 9.2 billion [2] - Haisen Pharmaceutical announced that some directors and senior management completed their share reduction plans, while one executive, based on confidence in the company's future, decided to terminate their plan early [2] - The financial director of Haisen Pharmaceutical reduced 3,000 shares during the planned period, while other executives completed their reductions totaling 102,900 shares, representing 0.0675% of the total share capital [2] Group 3 - AoJing Medical disclosed that its executives decided to terminate their share reduction plans early due to market conditions and personal circumstances [3] - Executives at AoJing Medical had previously planned to reduce their stakes from December 3, 2025, to March 3, 2026, but opted to halt the plan [3] - The reductions by executives at AoJing Medical accounted for 0.07%, 0.05%, 0.04%, and 0.03% of the total share capital, respectively [3]

Core Viewpoint - The company announced an abnormal stock price fluctuation with a cumulative increase of 20.95% over three consecutive trading days, deviating from the Shanghai Composite Index by 21.47% [1] Financial Performance - For the period from January to September 2025, the company's net profit attributable to shareholders was 172.5 million yuan, representing a year-on-year decrease of 12.06% [1] Corporate Actions - The company plans to acquire assets and raise funds, pending regulatory review [1] - The general manager and board member, Zhang Chuqian, along with his concerted actions, reduced their holdings by a total of 4.0598 million shares, accounting for 1.23% of the total share capital on December 8 [1] - On December 12, the company decided to terminate the share reduction plan early, committing not to reduce holdings from December 13, 2025, to December 12, 2026 [1]

Core Viewpoint - Hengbo Co., Ltd. announced that its shareholder, Hainan Mingxu Enterprise Management Partnership (Limited Partnership), had initially planned to reduce its holdings within three months after the announcement of the reduction plan, but ultimately did not sell any shares during the designated period [1] Summary by Relevant Sections - **Shareholder Reduction Plan** - Hainan Mingxu intended to reduce its holdings by up to 3.00% of the company's total share capital, excluding repurchased shares, which amounts to a maximum of 304.4 million shares [1] - The plan included a limit of no more than 1% reduction through centralized bidding and 2% through block trading within any consecutive 90 natural days [1] - **Current Shareholding Status** - As of the expiration of the reduction plan, Hainan Mingxu did not reduce any shares and continues to hold 3.67 million shares, representing 3.62% of the total share capital [1]